CytomX looks for $100M in IPO; FDA tells Fibrocell to do a new animal tox study;

@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: Novo scores a game-changing diabetes approval, reversing an embarrassing rejection. Article | Follow @JohnCFierce

@DamianFierce: Here's what it's like to try to get Sovaldi in my home town. More from The Atlantic | Follow @DamianFierce

> Looking to jump into a turbulent market, CytomX ($CTMX) set its IPO range at $14 to $16 a shares, looking to sell 6.7 million shares. At the mid-range point that would raise about $100 million. Story

> Fibrocell and Intrexon announced late last week that the FDA wants the company to perform a new animal study on the toxicity of its gene therapy drug FCX-007 before launching a clinical trial. Release

Medical Device News

@FierceMedDev: ICYMI: In latest biopharma-med tech pairing, Teva snaps up respiratory compliance tracker Gecko. More | Follow @FierceMedDev

@StacyALawrence: JDRF, ADA redefine Type 1 diabetes framework to encourage early diagnosis, prevention. Story | Follow @StacyALawrence

@VarunSaxena2: From @FierceMedDev's special report on recalls: Patients struggle to safely use HeartWare's blood pump. More | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Shire chalks up victory in Vyvanse patent battle. Article | Follow @EmilyWFierce

> Medtronic to buy stent retriever cover startup Lazarus Effect for $100M. Report

> Intestinal resurfacing procedure to treat diabetes shows promise in early stage trial. Article

Pharma News

@FiercePharma: AKC-funded study IDs similar lymphoma gene types in dogs and people. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Sun Pharma unit Mutual Pharma recalls 216,766 bottles that may have chemical leaching labels. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Roche is 'well placed' for U.S. pricing tussle, CEO says. Report | Follow @CarlyHFierce

> Novo combats talk of insulin price war with 'moderate premium' on brand-new Tresiba. Story

> How much more does the U.S. pay for drugs? Up to 10 times more, report says. Article

Animal Health News

> USDA unveils plan to battle avian flu if it re-emerges this fall. Story

> Sanofi rumored to be weighing Merial spinoff. Report

> Investors trounce Aratana on dashed hopes for canine lymphoma drugs. More

> AKC-funded study IDs similar lymphoma gene types in dogs and people. Story

> Rhizen moves into midstage trial of pill to treat canine lymphoma. Article

Biotech IT News

> BioClinica buys pharmacovigilance outfit to continue evolution. Article

> AstraZeneca opens data vault for cancer combo efficacy prediction challenge. Report

> Feds prioritize researcher access to health data in IT action plan. More

> Bayer pairs Genedata Profiler and iRODS to manage omics data analysis. Story

> Venter's HLI strikes low-cost exome sequencing deal to swell data repository. Article

Pharma Marketing News

> International payer report shows U.S. prices almost 10X higher for some meds. Item

> Novartis backs DC Comics graphic novel starring rare-disease hero and his canine sidekick. More

> NEJM: FDA's proposed risk-disclosure guidelines still aren't enough. Story

> Don't be quick to peg Merck's Keytruda in second place for NSCLC, analyst says. Article

> Not so fast, Hillary. Ad industry will fight with pharma against DTC tax moves. More

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.